Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

Yoshihiro Kanemitsu, Hisako Matsumoto, Kenji Izuhara, Yuji Tohda, Hideo Kita, Takahiko Horiguchi, Kazunobu Kuwabara, Keisuke Tomii, Kojiro Otsuka, Masaki Fujimura, Noriyuki Ohkura, Katsuyuki Tomita, Akihito Yokoyama, Hiroshi Ohnishi, Yasutaka Nakano, Tetsuya Oguma, Soichiro Hozawa, Tadao Nagasaki, Isao Ito, Tsuyoshi OgumaHideki Inoue, Tomoko Tajiri, Toshiyuki Iwata, Yumi Izuhara, Junya Ono, Shoichiro Ohta, Mayumi Tamari, Tomomitsu Hirota, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Background: Periostin, an extracellular matrix protein, contributes to subepithelial thickening in asthmatic airways, and its serum levels reflect airway eosinophilic inflammation. However, the relationship between periostin and the development of airflow limitation, a functional consequence of airway remodeling, remains unknown. Objective: We aimed to determine the relationship between serum periostin levels and pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. Methods: Two hundred twenty-four asthmatic patients (average age, 62.3 years) treated with ICS for at least 4 years were enrolled. Annual changes in FEV1, from at least 1 year after the initiation of ICS treatment to the time of enrollment or later (average, 16.2 measurements over 8 years per individual), were assessed. At enrollment, clinical indices, biomarkers that included serum periostin, and periostin gene polymorphisms were examined. Associations between clinical indices or biomarkers and a decline in FEV1 of 30 mL or greater per year were analyzed. Results: High serum periostin levels (≥95 ng/mL) at enrollment, the highest treatment step, higher ICS daily doses, a history of admission due to asthma exacerbation, comorbid or a history of sinusitis, and ex-smoking were associated with a decline in FEV1 of 30 mL or greater per year. Multivariate analysis showed that high serum periostin, the highest treatment step, and ex-smoking were independent risk factors for the decline. Polymorphisms of periostin gene were related to higher serum periostin levels (rs3829365) and a decline in FEV1 of 30 mL or greater per year (rs9603226). Conclusions: Serum periostin appears to be a useful biomarker for the development of airflow limitation in asthmatic patients on ICS.

Original languageEnglish
Pages (from-to)305-312.e3
JournalJournal of Allergy and Clinical Immunology
Volume132
Issue number2
DOIs
Publication statusPublished - 08-2013

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids'. Together they form a unique fingerprint.

  • Cite this

    Kanemitsu, Y., Matsumoto, H., Izuhara, K., Tohda, Y., Kita, H., Horiguchi, T., Kuwabara, K., Tomii, K., Otsuka, K., Fujimura, M., Ohkura, N., Tomita, K., Yokoyama, A., Ohnishi, H., Nakano, Y., Oguma, T., Hozawa, S., Nagasaki, T., Ito, I., ... Mishima, M. (2013). Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. Journal of Allergy and Clinical Immunology, 132(2), 305-312.e3. https://doi.org/10.1016/j.jaci.2013.04.050